Skip to main content
. 2009 Sep;158(2):610–620. doi: 10.1111/j.1476-5381.2009.00341.x

Figure 3.

Figure 3

(A) In vitro effects of oxaliplatin (LOHP) combined with cetuximab (CTX) in HT29-D4 control cells compared with HT29-D4 cells transfected with HA-tagged RasV12. Insert shows immunoblot for HA in transfected HT29-D4 cells. (B) IC50 values for oxaliplatin alone or combined with cetuximab on RasV12-transfected HT29-D4 cells compared with HT29-D4 control cells. *P < 0.05.